Videos

A randomized trial comparing survivorship care plans with standard oncologist discharge visits in patients with breast cancer found no differences in outcomes among the groups.

Dr. Debu Tripathy from USC Norris Cancer Center Describes the Benefits of the PER Conferences

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Recent study findings raise questions about how well computers interpret mammograms.

An exploratory analysis of the phase III EMBRACE trial of eribulin mesylate in metastatic breast cancer found the survival benefit and toxicity profile to be independent of age.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Patient Acceptance of Mutation Testing

On July, 29, 2011, a US appeals court sided with Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes.

Postmenopausal women at risk of breast cancer got good news from the MAP.3 trial results: Exemestane reduced their risk of invasive breast cancer by 65% compared with placebo.

Dr. Sandhya Pruthi from the Mayo Clinic in Minnesota on What She Learned From the Flaxseed Trial

It had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.

Dr. Sandya Pruthi from the Mayo Clinic in Minnesota Examines the Options Available for Hot Flashes after the failure of flaxseed

Dr. Mark G. Kris from Memorial Sloan-Kettering cancer center Explains How Gene Signatures are Used

The American College of Obstetricians and Gynecologists this week recommended annual mammography screenings for women starting at age 40.

The NCCN voted to maintain the current recommendation and position on Avastin (bevacizumab) in its treatment of metastatic breast cancer.

The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.

A panel voted 9-6 advising the FDA not to approve dapagliflozin, a diabetes drug that forces the body to dump sugar.

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design

Dr. Sandhya Pruthi from the Mayo Clinic Explains the Flaxseed for Hot Flashes Trial Results

Treatment with Herceptin, chemotherapy, or surgery extended the lives of patients with HER2-positive MBC following a diagnosis of CNS metastases.

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center on Breast Cancer with Bone Metastases

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

A phase III study of Afinitor (everolimus) tablets combined with exemestane in women with breast cancer revealed that the regime significantly extended PFS.

Although researchers know that estrogen plays a role in most cases of breast cancer, they don't fully understand how.

Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits